ARCHIVES

Ibrutinib Demonstrates 71% ORR In Phase Ib/II CLL and SLL Study

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Wilex, Fox Chase, Begin Trial Of WX-UK1 Targeting Invasion

May 28, 2004

Duke wins Avon-NCI funding.

October 31, 2003

Sausville to lead clinical research at Maryland.

December 5, 2003

BRCA Status Can Guide Ovarian Cancer Treatment

April 25, 2008

Patient Advocacy: Breast Cancer Coalition To Hold International Meeting In Brussels

January 17, 1997

NCI-DOD Agreement Could Be Model For Similar Project With HCFA, Lee Says

March 8, 1996